Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	40.59	23.61	27.46	10.16	28.65	13.29
Revenue Growth (YoY)	46.47%	-14.02%	170.26%	-64.53%	115.61%	3.50%
Cost of Revenue	8.59	7.42	2.17	0.22	2.06	1.31
Gross Profit	32	16.2	25.29	9.94	26.59	11.98
Selling, General & Admin	64.53	54.92	35.09	15.61	9.23	8.44
Research & Development	33.03	42.04	39.03	19.23	9.64	8.32
Operating Expenses	103.88	103.2	74.89	34.84	18.86	16.76
Operating Income	-71.88	-87	-49.6	-24.9	7.73	-4.78
Interest Expense	-8.59	-7.35	-1.5	-0.34	-0.38	-7.09
Interest & Investment Income	1.79	2.18	4.54	1.51	0.26	0.09
Other Non Operating Income (Expenses)	3.3	2.06	-0.1	15.16	-0.03	-0.18
EBT Excluding Unusual Items	-75.37	-90.12	-46.66	-8.57	7.59	-11.97
Merger & Restructuring Charges	-	-	-	-	-	-0.83
Gain (Loss) on Sale of Investments	0.01	-0.02	0.61	-0.58	-0.01	-
Other Unusual Items	-	-	-	-	-16.1	-
Pretax Income	-75.37	-90.14	-46.05	-26.81	-8.52	-12.79
Income Tax Expense	16.62	15.37	-	-0.03	0.03	-0.03
Net Income	-91.99	-105.51	-46.05	-26.77	-8.56	-12.76
Preferred Dividends & Other Adjustments	-	-	-	-	54.34	-
Net Income to Common	-91.99	-105.51	-46.05	-26.77	-62.9	-12.76
Shares Outstanding (Basic)	49	46	35	34	30	4
Shares Outstanding (Diluted)	49	46	35	34	30	4
Shares Change (YoY)	32.32%	30.46%	2.79%	15.87%	647.72%	114.79%
EPS (Basic)	-1.86	-2.28	-1.30	-0.78	-2.11	-3.21
EPS (Diluted)	-1.86	-2.28	-1.30	-0.78	-2.11	-3.21
Free Cash Flow	-61.82	-69.67	-33.83	-18.81	10.34	-1.97
Free Cash Flow Per Share	-1.25	-1.51	-0.95	-0.55	0.35	-0.49
Gross Margin	78.84%	68.59%	92.09%	97.81%	92.81%	90.18%
Operating Margin	-177.09%	-368.47%	-180.63%	-245.07%	26.98%	-35.98%
Profit Margin	-226.64%	-446.85%	-167.69%	-263.48%	-219.54%	-96.03%
Free Cash Flow Margin	-152.31%	-295.04%	-123.20%	-185.12%	36.08%	-14.84%
EBITDA	-65.4	-80.61	-48.6	-23.96	7.99	-4.51
EBITDA Margin	-161.14%	-	-176.97%	-235.78%	27.87%	-33.92%
D&A For EBITDA	6.48	6.39	1.01	0.94	0.26	0.27
EBIT	-71.88	-87	-49.6	-24.9	7.73	-4.78
EBIT Margin	-177.09%	-	-180.63%	-245.07%	26.98%	-35.98%

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q